Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter, Open-Label Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis Flares in Axial Spondyloarthritis Subjects With a History of Anterior Uveitis (C-VIEW)

Next Previous
Trial Profile

Multicenter, Open-Label Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis Flares in Axial Spondyloarthritis Subjects With a History of Anterior Uveitis (C-VIEW)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Certolizumab pegol (Primary)
  • Indications Ankylosing spondylitis; Anterior uveitis; Axial spondyloarthritis
  • Focus Therapeutic Use
  • Acronyms C-VIEW
  • Sponsors UCB Biopharma

    • Most Recent Events

    • 15 Nov 2023 Results assessing efficacy certolizumab pegol (CZP) compared with standard non-biologic care, presented at the ACR Convergence 2023.
    • 05 Jun 2021 Results assessing the 2-year outcomes and impact of certolizumab pegol treatment on acute anterior uveitis in patients with active ankylosing spondylitis, presented at the 22nd Annual Congress of the European League Against Rheumatism.
    • 01 Jun 2021 According to an UCB Media Release, results from a post hoc analysis of this trial will be presented at the European Congress of Rheumatology (EULAR) 2021.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top